PFIZER INCPFE損益計算書

時価総額
$1437.8億
PER
研究開発型グローバルバイオ医薬品の最大手(1942年6月設立)。ワクチンや医薬品(Comirnaty、Paxlovid等)を展開。2022年にBiohavenを約118億ドルで買収、同年にArenaを約66億ドルで買収。約200カ国・地域に供給。
2010/122011/122012/122013/122014/122015/122016/122017/122018/122019/122020/122021/122022/122023/122024/12
売上高67,80967,42558,98651,58449,60548,85152,82452,54653,64751,75041,90881,288100,33058,49663,627
売上成長率(%)-
売上原価16,27915,08511,3349,5869,5779,64812,32911,24011,24810,2198,69230,82134,34424,95417,851
販売管理費19,61419,46816,61614,35514,09714,80914,83714,78414,45514,35011,61512,70313,67714,77114,730
経常(税引前)利益9,42212,76212,08015,71612,2408,9658,35112,30511,88517,6827,49724,31134,7291,0588,023
経常(税引前)利益率(%)13.918.920.530.524.718.415.823.422.234.217.929.934.61.812.6
法人税等合計1,1244,0232,5624,3063,1201,9901,123-9,0497061,3844771,8523,328-1,100-28
実効税率(%)
純利益8,28910,05114,59822,0729,1686,9867,24621,35511,18816,3029,65222,02531,4072,1588,062
純利益率(%)
一株あたり利益1.031.281.963.231.441.131.183.571.92.921.733.925.590.381.42
希薄化後一株あたり利益1.021.271.943.191.421.111.173.521.872.871.713.855.470.371.41
配当性向(%)--
一株あたり配当金--0.880.961.041.121.21.281.381.461.531.571.611.651.69